Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Biogazelle Serves as Reference Laboratory for Bio-Rad's ddPCR System

Published: Monday, September 30, 2013
Last Updated: Monday, September 30, 2013
Bookmark and Share
Biogazelle’s and Bio-Rad’s long-term partnership extends.

Biogazelle has announced that it is serving a reference laboratory for Bio-Rad’s QX200™ Digital Droplet PCR™ system (ddPCR) in Europe. This extends Biogazelle’s and Bio-Rad’s long-term partnership for PCR-based solutions.

As a reference laboratory, Biogazelle uses ddPCR in its R&D programs and shares its ddPCR user experience with the PCR community.

In addition, Biogazelle is acting as a ddPCR service provider for third parties who are interested in outsourcing a study. In addition, the Biogazelle laboratory also serves as a live research environment for prospective QX200 system customers.

Professor Jo Vandesompele, co-founder of Biogazelle, welcomes the agreement: "We are a young and dynamic company, eager to learn from and to teach the PCR research community. Being a reference center for ddPCR is completely in line with our mission to address unmet needs through excellence in science and technology."

Digital PCR is a nucleic acid quantification method with unprecedented resolution and relative sensitivity. It can determine how many nucleic acid target molecules are present in a particular sample by counting how many miniaturized reactions are positive if the template is partitioned into 1000’s of parallel reactions.

The QX200 system uses droplets as partitions to perform ddPCR. It is a flexible and high throughput instrument with an optimal number of partitions per sample. Both probe and dye based assays can be used.

Biogazelle is at the forefront of digital PCR-based research, as it was one of the first European laboratories that had access to the technology in 2012. The co-founders are also co-author on the digital MIQE guidelines (Huggett et al., Clinical Chemistry, 2013).

Biogazelle is working on various ddPCR projects, including (i) gene copy number quantification to determine the stability of transgenic cells or organisms, (ii) splice variant quantification, (iii) quantification of pathogenic organisms, and (iv) rare event detection for cancer diagnostics and monitoring of patient response to treatment.

By sharing its expertise in assay development, experiment design and nucleic acid quantification, Biogazelle aims to serve the digital PCR community. In addition, Biogazelle will use its experience to provide digital PCR services for academic and industrial customers.

Dr. Jan Hellemans, co-founder of Biogazelle, acknowledges the great potential digital PCR holds for clinical diagnostics. "Data interpretation is quite straightforward and results can easily be shared and interpreted among different users because absolute concentrations are determined. Moreover, its inherently high precision, accuracy and relative sensitivity are relevant features for laboratory tests that are used in the clinic. Biogazelle is proud to accelerate ddPCR discoveries, bringing ddPCR closer to the clinic."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Biogazelle Receives €1.1M IWT Funding
Funding to develop lncRNA targeting cancer therapies.
Wednesday, August 12, 2015
Biogazelle has Established a Quality Management System
Company is ISO 17025 accredited for gene expression services.
Tuesday, February 03, 2015
Biogazelle Attracts New Investors
UGent spin-off Biogazelle attracts new investors QBIC Arkiv Fund, Foundation Majoie and SOFI to finance growth.
Tuesday, October 07, 2014
VIB Inks qBase+ Group Licensing Agreement with Biogazelle
VIB to accelerate its qPCR analyses by using qbase+ as the software.
Monday, May 20, 2013
Biogazelle Appoints Kris Vanhercke as Chief Operating Officer
New appointment strengthens business development and marketing expertise of Biogazelle.
Monday, September 24, 2012
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!